作者：
Paolo Antonio,Ascierto [1]
;
Lorenzo,Borgognoni [2]
;
Gerardo,Botti [3]
;
Michele,Guida [4]
;
Paolo,Marchetti [5]
;
Simone,Mocellin [6]
;
Paolo,Muto [3]
;
Giuseppe,Palmieri [7]
;
Roberto,Patuzzo [8]
;
Pietro,Quaglino [9]
;
Ignazio,Stanganelli [10]
;
Corrado,Caracò [11]
作者单位：
Unit Melanoma, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy. paolo.ascierto@gmail.com.
[1]
Ospedale Santa Maria Annunziata and University of Florence, Florence, Italy.
[2]
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.
[3]
Unit Melanoma and Rare Tumors, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
[4]
Oncologia Medica B Policlinico Umberto I di Roma, Rome, Italy.
[5]
Surgical Oncology Unit, IOV-IRCCS of Padova and Dept. Surgery Oncology Gastroenterology, University of Padova, Padua, Italy.
[6]
Unit of Cancer Genetics, ICB-CNR, Sassari, Italy.
[7]
Research Director CNR, Italian Melanoma Intergroup (IMI), Unit of Cancer Genetics, Head Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy.
[8]
IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy.
[9]
Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy.
[10]
Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, FC, Italy.
[11]
University of Parma, Parma, Italy.
[12]
DOI
10.1186/s12967-019-2012-2
PMID
31412885
发布时间
2020-06-22
换一批
换一批
